Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. Cancer J Clin. 2024;74(1):12–49.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49.

Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (London England). 2021;41(10):1037–48.

Article  Google Scholar 

Patel TH, Cecchini M. Targeted therapies in Advanced Gastric Cancer. Curr Treat Options Oncol. 2020;21(9):70.

Article  PubMed  Google Scholar 

Chao J, Fuchs CS, Shitara K, Tabernero J, Muro K, Van Cutsem E, Bang YJ, De Vita F, Landers G, Yen CJ, et al. Assessment of Pembrolizumab Therapy for the treatment of microsatellite instability-high gastric or gastroesophageal Junction Cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 2021;7(6):895–902.

Article  PubMed  PubMed Central  Google Scholar 

Guan WL, Ma Y, Cui YH, Liu TS, Zhang YQ, Zhou ZW, Xu JY, Yang LQ, Li JY, Sun YT, et al. The impact of Mismatch Repair Status on prognosis of patients with gastric Cancer: a Multicenter Analysis. Front Oncol. 2021;11:712760.

Article  PubMed  PubMed Central  Google Scholar 

Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, et al. Safety and Efficacy of Pembrolizumab Monotherapy in patients with previously treated Advanced gastric and gastroesophageal Junction Cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013.

Article  PubMed  PubMed Central  Google Scholar 

Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, et al. Efficacy and safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy alone for patients with First-line, Advanced Gastric Cancer: the KEYNOTE-062 phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(10):1571–80.

Article  PubMed  Google Scholar 

Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet (London England). 2018;392(10142):123–33.

Article  CAS  PubMed  Google Scholar 

Liu Z, Zhang S. Toward a systematic understanding of cancers: a survey of the pan-cancer study. Front Genet. 2014;5:194.

Article  PubMed  Google Scholar 

Vizcaíno C, Mansilla S, Portugal J. Sp1 transcription factor: a long-standing target in cancer chemotherapy. Pharmacol Ther. 2015;152:111–24.

Article  PubMed  Google Scholar 

Safe S, Imanirad P, Sreevalsan S, Nair V, Jutooru I. Transcription factor Sp1, also known as specificity protein 1 as a therapeutic target. Expert Opin Ther Targets. 2014;18(7):759–69.

Article  CAS  PubMed  Google Scholar 

Hang J, Hu H, Huang J, Han T, Zhuo M, Zhou Y, Wang L, Wang Y, Jiao F, Wang L. Sp1 and COX2 expression is positively correlated with a poor prognosis in pancreatic ductal adenocarcinoma. Oncotarget. 2016;7(19):28207–17.

Article  PubMed  Google Scholar 

Dong X, Liu Z, Zhang E, Zhang P, Wang Y, Hang J, Li Q. USP39 promotes tumorigenesis by stabilizing and deubiquitinating SP1 protein in hepatocellular carcinoma. Cell Signal. 2021;85:110068.

Article  CAS  PubMed  Google Scholar 

Seznec J, Silkenstedt B, Naumann U. Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma. J Neurooncol. 2011;101(3):365–77.

Article  CAS  PubMed  Google Scholar 

Lin RK, Wu CY, Chang JW, Juan LJ, Hsu HS, Chen CY, Lu YY, Tang YA, Yang YC, Yang PC, et al. Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. Cancer Res. 2010;70(14):5807–17.

Article  CAS  Google Scholar 

Monteleone E, Orecchia V, Corrieri P, Schiavone D, Avalle L, Moiso E, Savino A, Molineris I, Provero P, Poli V. SP1 and STAT3 Functionally Synergize to Induce the RhoU Small GTPase and a Subclass of Non-canonical WNT Responsive Genes Correlating with Poor Prognosis in Breast Cancer. Cancers 2019, 11(1).

Oleaga C, Welten S, Belloc A, Solé A, Rodriguez L, Mencia N, Selga E, Tapias A, Noé V, Ciudad CJ. Identification of novel Sp1 targets involved in proliferation and cancer by functional genomics. Biochem Pharmacol. 2012;84(12):1581–91.

Article  CAS  PubMed  Google Scholar 

Gilmour J, Assi SA, Jaegle U, Kulu D, van de Werken H, Clarke D, Westhead DR, Philipsen S, Bonifer C. A crucial role for the ubiquitously expressed transcription factor Sp1 at early stages of hematopoietic specification. Development. 2014;141(12):2391–401.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xie J, Gong Q, Liu X, Liu Z, Tian R, Cheng Y, Su G. Transcription factor SP1 mediates hyperglycemia-induced upregulation of roundabout4 in retinal microvascular endothelial cells. Gene. 2017;616:31–40.

Article  CAS  PubMed  Google Scholar 

Gong L, Wen T, Li Z, Wang Y, Wang J, Che X, Liu Y, Qu X. TNPO2 operates downstream of DYNC1I1 and promotes gastric cancer cell proliferation and inhibits apoptosis. Cancer Med. 2019;8(17):7299–312.

Article  CAS  PubMed  Google Scholar 

Cao C, Xu Q, Zhu Z, Xu M, Wei Y, Lin S, Cheng S, Zhi W, Hong P, Huang X, et al. Three-dimensional chromatin analysis reveals Sp1 as a mediator to program and reprogram HPV-host epigenetic architecture in cervical cancer. Cancer Lett. 2024;588:216809.

Article  CAS  PubMed  Google Scholar 

Beishline K, Azizkhan-Clifford J. Sp1 and the ‘hallmarks of cancer’. FEBS J. 2015;282(2):224–58.

Article  CAS  PubMed  Google Scholar 

Safe S. Specificity proteins (sp) and Cancer. Int J Mol Sci 2023, 24(6).

Wang L, Wei D, Huang S, Peng Z, Le X, Wu TT, Yao J, Ajani J, Xie K. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin cancer Research: Official J Am Association Cancer Res. 2003;9(17):6371–80.

CAS  Google Scholar 

Gu L, Sang M, Li J, Liu F, Wu Y, Liu S, Wang P, Shan B. Expression and prognostic significance of MAGE-A11 and transcription factors (SP1,TFCP2 and ZEB1) in ESCC tissues. Pathol Res Pract. 2019;215(7):152446.

Article  CAS  PubMed  Google Scholar 

Hu J, Hu H, Hang JJ, Yang HY, Wang ZY, Wang L, Chen DH, Wang LW. Simultaneous high expression of PLD1 and Sp1 predicts a poor prognosis for pancreatic ductal adenocarcinoma patients. Oncotarget. 2016;7(48):78557–65.

Article  PubMed  Google Scholar 

Ji H, Wang J, Lu B, Li J, Zhou J, Wang L, Xu S, Peng P, Hu X, Wang K. SP1 induced long non-coding RNA AGAP2-AS1 promotes cholangiocarcinoma proliferation via silencing of CDKN1A. Molecular medicine (Cambridge, Mass) 2021, 27(1):10.

Bartella V, Rizza P, Barone I, Zito D, Giordano F, Giordano C, Catalano S, Mauro L, Sisci D, Panno ML, et al. Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter. Breast Cancer Res Treat. 2012;134(2):569–81.

Article  CAS  PubMed  Google Scholar 

Bravo ML, Pinto MP, Gonzalez I, Oliva B, Kato S, Cuello MA, Lange CA, Owen GI. Progesterone regulation of tissue factor depends on MEK1/2 activation and requires the proline-rich site on progesterone receptor. Endocrine. 2015;48(1):309–20.

Article  CAS  PubMed  Google Scholar 

Pu H, Wen X, Luo D, Guo Z. Regulation of progesterone receptor expression in endometriosis, endometrial cancer, and breast cancer by estrogen, polymorphisms, transcription factors, epigenetic alterations, and ubiquitin-proteasome system. J Steroid Biochem Mol Biol. 2023;227:106199.

Article  CAS  PubMed  Google Scholar 

Zou C, Li W, Zhang Y, Feng N, Chen S, Yan L, He Q, Wang K, Li W, Li Y, et al. Identification of an anaplastic subtype of prostate cancer amenable to therapies targeting SP1 or translation elongation. Sci Adv. 2024;10(14):eadm7098.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coelho M, Capela J, Anjo SI, Pacheco J, Fernandes MS, Amendoeira I, Jones JG, Raposo L, Manadas B. Proteomics reveals mRNA regulation and the action of annexins in thyroid Cancer. Int J Mol Sci 2023, 24(19).

Guan H, Cai J, Zhang N, Wu J, Yuan J, Li J, Li M. Sp1 is upregulated in human glioma, promotes MMP-2-mediated cell invasion and predicts poor clinical outcome. Int J Cancer. 2012;130(3):593–601.

Article  CAS  PubMed  Google Scholar 

Xiao X, Chen M, Sang Y, Xue J, Jiang K, Chen Y, Zhang L, Yu S, Lv W, Li Y, et al. Methylation-mediated silencing of ATF3 promotes thyroid Cancer progression by regulating prognostic genes in the MAPK and PI3K/AKT pathways. Thyroid: Official J Am Thyroid Association. 2023;33(12):1441–54.

Article  CAS  Google Scholar 

Situ Y, Liang Q, Zeng Z, Chen J, Shao Z, Xu Q, Lu X, Cui Y, Zhang J, Lu L, et al. Systematic analysis of the BET family in adrenocorti